Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
Express Scripts
Johnson and Johnson
AstraZeneca

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for VTP-27999

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug VTP-27999: Patents, clinical trial progress, indications

VTP-27999 is an investigational drug.

There have been 16 clinical trials for VTP-27999. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Neovascularization, Pathologic. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.

There are four US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for VTP-27999
TitleSponsorPhase
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate CancerInternational Drug Development InstitutePhase 4
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate CancerPrimeVigilance LTDPhase 4
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate CancerSteba Biotech S.A.Phase 4

See all VTP-27999 clinical trials

Clinical Trial Summary for VTP-27999

Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999

See all VTP-27999 clinical trials

US Patents for VTP-27999

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VTP-27999   Start Trial Piperidine renin inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Start Trial
VTP-27999   Start Trial Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-p- yran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Start Trial
VTP-27999   Start Trial Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.